Collaborative Clinical Trials
HLHRUXO: Ruxolitinib Therapy for HLH
HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis
Diseases Treated:
Hemophagocytic Lymphohistiocytosis
Eligibility:
- 6 weeks to 22 years old
- Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
- Relapsed or refractory HLH
HSESID: Database for HLH Immunodeficiency Disease
A Registry for Hemophagocytic Lymphohistiocytosis (HLH)
Eligibility:
- Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
- Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
- High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
LCH-IV: Clinical Trial for Children and Adolescents with Langerhans Cell Histiocytosis
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
Diseases Treated:
Eligibility:
- Diagnosis of Langerhans cell histiocytosis
- Younger than 18 years old
- Meets inclusion criteria for the respective stratum